AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A process for producing an antibody against a glypican protein comprising immunizing a mouse with Fas function defects that develops autoimmune disease with a human glypican protein.

2. (Previously Presented) A process for producing an antibody against a glypican protein comprising immunizing an autoantibody-producing mouse with Fas function defects with a human glypican protein.

3. - 4. (Canceled)

5. (Previously Presented) The process for producing an antibody against a glypican protein according to claim 1 or 2, wherein the mouse is the MRL/lpr mouse.

6. (Previously Presented) The process for producing an antibody against a glypican protein according to claim 1, wherein the glypican protein is glypican 3.

7. (Currently Amended) A process for producing an antibody comprising immunizing a mouse with Fas function defects with a human native protein, ~~which has~~ wherein said human native protein has a sequence identity of 94% or more at the amino acid sequence level to a homolog protein over the whole length, of the mouse to be immunized.

8. (Canceled)

9. (Previously Presented) The process for producing an antibody according to claim 7, wherein the mouse is the MRL/lpr mouse.

10-12. (Canceled)

13. (Previously Presented) The process of claim 1, wherein said autoimmune disease is systemic erythematosous.

14. (Previously Presented) The process of claim 7, wherein said Fas function defects comprises at least survival of B cells that respond to an autoantigen and produce an excess amount of autoantibody as compared to normally functional B cells.

15. (Withdrawn) The process of claim 7, wherein said Fas function defect is caused by a mutation in the Fas ligand gene.

16. (Previously Presented) The process of claim 7, wherein said mouse has abnormal T cell accumulation as compared to a normal mouse, and wherein said mouse has a systemic erythematosous-like autoimmune disease.

17. (Withdrawn) The process of claim 7, wherein said mouse is selected from the group consisting of a MRL/gld mouse, a MRL/Mp-+/+ mouse, a NZB/NZW F1 mouse, a BXSB/MpJ mouse, a B/WF1 mouse, a BXSB mouse and a SL/Ni mouse.

18. (Previously Presented) The process of claim 7, wherein said mouse is a mouse in which expression of Fas or Fas ligand is artificially repressed.

19. – 20. (Canceled).

21. (Previously Presented) The process of claim 1 or 2, wherein said Fas function defects comprises at least survival of B cells that respond to an autoantigen and produce an excess amount of autoantibody when compared to normally functional B cells.

22. (Withdrawn) The process of claim 1 or 2, wherein said Fas function defect is caused by a mutation in the Fas ligand gene.

23. (Canceled)

24. (Withdrawn) The process of claim 1 or 2, wherein said mouse is selected from the group consisting of a MRL/gld mouse, a MRL/Mp-+/+ mouse, a NZB/NZW F1 mouse, a BXSB/MpJ mouse, a B/WF1 mouse, a BXSB mouse and a SL/Ni mouse.

25. (Canceled)

26. (New) The process for producing an antibody against a glypican protein according to claim 1, wherein the mouse is the MRL/lpr mouse and the protein is glypican 3.